Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors

NCT06631079 is registered in ClinicalTrials.gov with NEC Bio B.V as lead sponsor.

NCT NCT06631079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06631079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors
Lead sponsor
NEC Bio B.V
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 7, 2024
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor